Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: The Italian experience

Valeria L. Brunelli, G. Russo, S. Bertelloni, L. Gargantini, R. Balducci, L. Chiesa, C. Livieri, C. De Sanctis, S. Einaudi, R. Virdis, G. Saggese, G. Chiumello

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the influence of target height (TH), gender, phenotype, glucocorticoid formulation and age at onset of treatment on final height (FH) in patients with 21-hydroxylase deficiency (21OHD). Patients: Clinical data of 93 patients - 46 simple virilizing (SV), 35 salt-wasting (SW) and 12 late onset (LO) - were collected in six pediatric endocrinology units in Italy. Results: FH and TH were always below the mean height of the general population (mean FH, SDS: SW patients -1.3 ± 1.2, SV patients -1.8 ± 0.9, LO patients -1.7 ± 1.1; mean TH, SDS: SW patients -0.6 ± 0.8, SV patients -0.7 ± 0.9, LO patients -1.4 ± 1.3). FH was significantly below TH in patients with classic form (SW and SV, p

Original languageEnglish
Pages (from-to)277-283
Number of pages7
JournalJournal of Pediatric Endocrinology and Metabolism
Volume16
Issue numberSUPPL. 2
Publication statusPublished - 2003

Keywords

  • 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • Final height
  • Glucocorticoid substitutive treatment
  • Growth

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: The Italian experience'. Together they form a unique fingerprint.

  • Cite this

    Brunelli, V. L., Russo, G., Bertelloni, S., Gargantini, L., Balducci, R., Chiesa, L., Livieri, C., De Sanctis, C., Einaudi, S., Virdis, R., Saggese, G., & Chiumello, G. (2003). Final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: The Italian experience. Journal of Pediatric Endocrinology and Metabolism, 16(SUPPL. 2), 277-283.